Medivation Receives Buy Rating from Aegis (MDVN)
Medivation (NASDAQ:MDVN)‘s stock had its “buy” rating reiterated by Aegis in a research note issued on Tuesday, Stock Ratings News reports.
MDVN has been the subject of a number of other recent research reports. Analysts at Chardan Capital initiated coverage on shares of Medivation in a research note to investors on Wednesday, September 18th. They set a “buy” rating and a $72.00 price target on the stock. Separately, analysts at Zacks downgraded shares of Medivation from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, August 28th. They now have a $59.00 price target on the stock. Finally, analysts at Barclays cut their price target on shares of Medivation from $54.00 to $53.00 in a research note to investors on Monday, August 12th. They now have an “equal weight” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $65.73.
Medivation (NASDAQ:MDVN) traded up 4.06% during mid-day trading on Tuesday, hitting $51.845. 4,188,145 shares of the company’s stock traded hands. Medivation has a 1-year low of $41.89 and a 1-year high of $61.46. The stock has a 50-day moving average of $56.96 and a 200-day moving average of $53.91. The company’s market cap is $3.899 billion.
Medivation (NASDAQ:MDVN) last released its earnings data on Thursday, August 8th. The company reported ($0.07) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.14. The company had revenue of $70.15 million for the quarter, compared to the consensus estimate of $59.35 million. During the same quarter in the prior year, the company posted ($0.15) earnings per share. The company’s quarterly revenue was up 63.5% on a year-over-year basis.
Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.